Biogen Inc

24. Sept. 2026, 23:05 UTC

Biogen Inc is trading modestly higher in after-market hours, reflecting solid performance above its 20-day moving average and near the upper end of its one-month range.

23. Sept. 2026, 19:36 UTC

Biogen Inc is seeing modest gains as it releases adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI, targeting rare kidney diseases.

22. Sept. 2026, 23:50 UTC

Biogen Inc is trading lower in after-market hours, experiencing fluctuations despite remaining above its 20-day moving average and near the upper end of its one-month range.

21. Sept. 2026, 23:05 UTC

Biogen Inc. is trading slightly higher in after-market hours following approvals for at-home LEQEMBI in Japan and China and new Phase 3 data for EMPAVELI.

18. Sept. 2026, 20:02 UTC

Biogen Inc shares fell sharply, reversing a trend of higher daily closes observed in recent sessions and breaking from upward momentum since Thursday's close.

17. Sept. 2026, 20:07 UTC

Biogen Inc. shares advanced after Japan approved its subcutaneous formulation of LEQEMBI®, enhancing its Alzheimer's treatment portfolio in today's trading.

16. Sept. 2026, 20:21 UTC

Biogen Inc's LEQEMBI® receives approval in Japan for a new administration route, while the stock is modestly lower in after-market trading.

15. Sept. 2026, 20:07 UTC

Biogen Inc shares are lower today, influenced by a drop in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

14. Sept. 2026, 20:08 UTC

Biogen Inc. shares are advancing, supported by strong performances from key holdings in the health care sector. The broader market reflects modest gains.

11. Sept. 2026, 20:08 UTC

Biogen Inc is rising after Needham named it a top biotechnology pick, maintaining a Buy rating amid expectations for future growth and clinical developments.

10. Sept. 2026, 20:07 UTC

Stifel reiterated a Buy rating on Biogen and raised its price target to $242, while HSBC maintained a Reduce rating with a target increase to $175.

9. Sept. 2026, 20:07 UTC

Biogen Inc shares are lower in Wednesday's session, with no specific news identified. The broader market decline may be influencing the asset's performance.

8. Sept. 2026, 23:06 UTC

Biogen Inc shares are modestly higher in after-market trading, continuing positive sentiment since Tuesday's close. Broader market conditions reflect strong U.S. labor data.

4. Sept. 2026, 23:46 UTC

Biogen Inc shares are lower in after-market hours, with no specific news driving the decline. Broader economic signals are contributing to market uncertainty.

3. Sept. 2026, 19:16 UTC

Biogen and Eisai received approval for LEQEMBI in China for early Alzheimer's treatment. Piper Sandler raised Biogen's price target to $245, maintaining an Overweight rating.

2. Sept. 2026, 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

1. Sept. 2026, 21:01 UTC

Biogen Inc. shares are lower in after-market hours, continuing a downward trend over the past three sessions with no specific news identified.

31. Aug. 2026, 19:46 UTC

Biogen Inc's shares are lower amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh at the Jackson Hole symposium.

28. Aug. 2026, 21:01 UTC

Biogen Inc shares are lower in after-market hours, reflecting broader market weakness. No specific news was identified to explain the decline.

26. Aug. 2026, 20:08 UTC

Biogen Inc. has chosen Veeva Systems' Veeva Vault CRM to enhance its digital strategy, with shares rising during Wednesday's session amid positive sentiment.

25. Aug. 2026, 23:26 UTC

Biogen Inc. shares are trading roughly flat in after-market hours. Crude oil prices have declined, easing some geopolitical tensions, impacting overall market sentiment.

24. Aug. 2026, 20:13 UTC

Biogen Inc shares are trading lower in after-market hours. Broader market conditions may be influencing trading sentiment amid U.S.-Iran tensions and inflation concerns.

21. Aug. 2026, 20:06 UTC

Biogen Inc is trading higher since Thursday's close, reflecting positive market trends. The stock remains above its 20-day moving average despite a recent pullback.

20. Aug. 2026, 20:01 UTC

Shares lower today amid broader market declines and ETF drop.

19. Aug. 2026, 23:06 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Wednesday's close. The asset remains above its 20-day moving average.

17. Aug. 2026, 19:46 UTC

Biogen Inc. shares are lower today amid routine trading, despite an unexpected rise in the New York manufacturing index supporting broader market conditions.

14. Aug. 2026, 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting routine fluctuations. The stock remains above its 20-day moving average and near its monthly range high.

13. Aug. 2026, 20:06 UTC

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12. Aug. 2026, 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11. Aug. 2026, 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.